Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Sage Therapeutics	Arena Pharmaceuticals	Hutchison China MediTech	Reata Pharmaceuticals	PTC Therapeutics
Symbol	NASDAQ:SAGE	NASDAQ:ARNA	NASDAQ:HCM	NASDAQ:RETA	NASDAQ:PTCT
Price Information
Current Price	$73.25	$66.40	$29.63	$86.46	$47.30
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.4	1.7	1.4	1.4	1.3
Analysis Score	3.3	4.5	3.5	3.5	3.3
Community Score	3.1	2.4	2.7	2.6	2.5
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	1.7	0.0	0.8	0.0
Earnings & Valuation Score	0.6	0.0	0.6	0.0	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$87.06	$92.80	$40.00	$251.25	$64.90
% Upside from Price Target	18.86% upside	39.76% upside	35.00% upside	190.60% upside	37.21% upside
Trade Information
Market Cap	$4.20 billion	$4.01 billion	$4.31 billion	$3.13 billion	$3.33 billion
Beta	2.23	0.83	1.12	1.57	1.22
Average Volume	498,601	505,044	239,001	290,331	547,068
Sales & Book Value
Annual Revenue	$6.87 million	$806.43 million	$204.89 million	$26.52 million	$306.98 million
Price / Sales	622.49	4.97	21.05	118.02	10.84
Cashflow	N/A	$6.51 per share	N/A	N/A	N/A
Price / Cash	N/A	10.20	N/A	N/A	N/A
Book Value	$18.23 per share	$21.38 per share	$2.35 per share	$7.74 per share	$9.64 per share
Price / Book	4.02	3.11	12.61	11.17	4.91
Profitability
Net Income	$-680,240,000.00	$397.55 million	$-106,020,000.00	$-290,170,000.00	$-251,580,000.00
EPS	($13.38)	$7.69	($0.80)	($9.54)	($3.45)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-7,706.84%	N/A	N/A	-4,340.72%	-123.19%
Return on Equity (ROE)	-63.81%	-33.17%	N/A	-163.42%	-76.10%
Return on Assets (ROA)	-56.64%	-30.41%	N/A	-56.49%	-24.60%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.04%	0.07%	N/A	1.89%
Current Ratio	11.71%	23.17%	3.14%	12.98%	4.90%
Quick Ratio	11.71%	23.17%	3.01%	12.98%	4.83%
Ownership Information
Institutional Ownership Percentage	N/A	89.67%	33.45%	64.30%	N/A
Insider Ownership Percentage	4.80%	3.05%	N/A	31.70%	7.00%
Miscellaneous
Employees	298	363	1,280	261	959
Shares Outstanding	58.38 million	60.34 million	145.54 million	36.20 million	70.32 million
Next Earnings Date	5/6/2021 (Estimated)	5/6/2021 (Estimated)	N/A	5/10/2021 (Estimated)	4/29/2021 (Estimated)
Optionable	Optionable	Optionable	Not Optionable	Optionable	Optionable

Source	Headline
	RBC Capital Stick to Their Hold Rating for PTC Therapeutics investing.com - April 12 at 1:38 PM
	Zacks: Brokerages Expect PTC Therapeutics, Inc. (NASDAQ:PTCT) to Announce -$1.59 Earnings Per Share americanbankingnews.com - April 10 at 4:16 PM
	PTC Therapeutics Received Gallup's "Don Clifton Strengths-Based Culture" Award finance.yahoo.com - April 7 at 12:58 PM
	PTC Therapeutics to Host PTC518 Huntington Disease Deep Dive Webinar prnewswire.com - April 7 at 8:55 AM
	PTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi™ finance.yahoo.com - April 1 at 8:55 AM
	Roche, PTC Therapeutics Gets European OK of Evrysdi in Spinal Muscular Atrophy morningstar.com - March 30 at 10:37 AM
	PTC Therapeutics-Roche's Evrysdi Approved In Europe For Muscular Atrophy finance.yahoo.com - March 30 at 10:37 AM
	PTC Therapeutics Announces the European Approval of Evrysdi™ for the Treatment of Spinal Muscular Atrophy finance.yahoo.com - March 30 at 1:07 AM
	PTC Therapeutics (NASDAQ:PTCT) Upgraded to Sector Perform by Royal Bank of Canada americanbankingnews.com - March 29 at 11:12 AM
	PTC Therapeutics (NASDAQ:PTCT) Raised to Sector Perform at Royal Bank of Canada marketbeat.com - March 29 at 8:16 AM
	Results from the Second Year of Evrysdi™ (risdiplam) Treatment Demonstrated Sustained Improvement of Motor Function in a Broad Range of SMA Patients finance.yahoo.com - March 24 at 1:30 AM
	PTCT Makes Notable Cross Below Critical Moving Average nasdaq.com - March 23 at 3:15 PM
	PTC Therapeutics (NASDAQ:PTCT) Stock Price Down 7.1% americanbankingnews.com - March 23 at 12:00 PM
	Interesting PTCT Put And Call Options For May 21st nasdaq.com - March 23 at 10:09 AM
	PTC Therapeutics (NASDAQ:PTCT) Upgraded to "Hold" at Zacks Investment Research marketbeat.com - March 17 at 3:50 AM
	Results from the Second Year of Evrysdiâ¢ (risdiplam) Treatment Demonstrated Sustained Improvement of Motor Function in a Broad Range of SMA Patients markets.businessinsider.com - March 16 at 2:13 AM
	PTC Presents Results from a Real-World Study of Steroid Switching in the Treatment of Patients with Dystrophinopathies finance.yahoo.com - March 15 at 12:58 PM
	Spinal Muscular Atrophy (SMA) Foundation and PTC Therapeutics Expand Partnership to Advance Drug Discovery and Development Research in Regenerative Medicine finance.yahoo.com - March 9 at 9:15 AM
	CHMP Adopts Positive Opinion for Evrysdi(TM) for the Treatment of Spinal Muscular Atrophy in Adults and Children Aged Two Months and Older stockhouse.com - February 26 at 10:15 AM
	CHMP Adopts Positive Opinion for Evrysdi™ for the Treatment of Spinal Muscular Atrophy in Adults and Children Aged Two Months and Older finance.yahoo.com - February 26 at 10:15 AM
	PTC Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update markets.businessinsider.com - February 25 at 6:45 PM
	PTC Therapeutics, Inc. to Host Earnings Call finance.yahoo.com - February 25 at 6:45 PM
	Positive Data from FIREFISH Study of Evrysdi™ (risdiplam) in Infants with Type 1 Spinal Muscular Atrophy Published in The New England Journal of Medicine finance.yahoo.com - February 24 at 5:43 PM
	PTC Therapeutics Reports the Initiation of the Second Stage of the FITE19 Phase 2/3 Clinical Trial Evaluating PTC299 for the Treatment of COVID-19 finance.yahoo.com - February 17 at 9:28 AM
	Loss-Making PTC Therapeutics, Inc. (NASDAQ:PTCT) Expected To Breakeven In The Medium-Term finance.yahoo.com - February 15 at 10:20 AM
	PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results finance.yahoo.com - February 11 at 8:24 AM
	PTC Therapeutics to Host Call to Review Results from its Study of Translarna™ (ataluren) in Patients with Nonsense Mutation Duchenne Muscular Dystrophy finance.yahoo.com - February 4 at 7:41 PM

Date	Company	Brokerage	Action
4/12/2021	Sage Therapeutics	Mizuho	Reiterated Rating
4/7/2021	Sage Therapeutics	Piper Sandler	Initiated Coverage
3/8/2021	Sage Therapeutics	Morgan Stanley	Boost Price Target
3/3/2021	Sage Therapeutics	Oppenheimer	Boost Price Target
2/25/2021	Sage Therapeutics	HC Wainwright	Boost Price Target
2/1/2021	Sage Therapeutics	Raymond James	Initiated Coverage
1/22/2021	Sage Therapeutics	BMO Capital Markets	Downgrade
1/19/2021	Sage Therapeutics	Wedbush	Boost Price Target
1/4/2021	Sage Therapeutics	Guggenheim	Upgrade
1/4/2021	Sage Therapeutics	Royal Bank of Canada	Downgrade
12/4/2020	Sage Therapeutics	William Blair	Reiterated Rating
12/1/2020	Sage Therapeutics	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Lower Price Target
12/1/2020	Sage Therapeutics	Truist	Boost Price Target
12/1/2020	Sage Therapeutics	Smith Barney Citigroup	Lower Price Target
4/13/2021	Arena Pharmaceuticals	Credit Suisse Group	Boost Price Target
3/9/2021	Arena Pharmaceuticals	Cantor Fitzgerald	Lower Price Target
3/3/2021	Arena Pharmaceuticals	SVB Leerink	Lower Price Target
3/3/2021	Arena Pharmaceuticals	Jonestrading	Lower Price Target
11/2/2020	Arena Pharmaceuticals	JPMorgan Chase & Co.	Boost Price Target
9/30/2020	Arena Pharmaceuticals	Bank of America	Boost Price Target
8/6/2020	Arena Pharmaceuticals	Wells Fargo & Company	Boost Price Target
8/6/2020	Arena Pharmaceuticals	Needham & Company LLC	Reiterated Rating
10/2/2020	Hutchison China MediTech	Deutsche Bank Aktiengesellschaft	Initiated Coverage
2/20/2020	Hutchison China MediTech	The Goldman Sachs Group	Initiated Coverage
11/19/2019	Hutchison China MediTech	CLSA	Initiated Coverage
7/5/2019	Hutchison China MediTech	Macquarie	Initiated Coverage
3/27/2019	Hutchison China MediTech	HSBC	Initiated Coverage
8/10/2020	Reata Pharmaceuticals	Stifel Nicolaus	Lower Price Target
6/16/2020	Reata Pharmaceuticals	BTIG Research	Initiated Coverage
6/12/2020	Reata Pharmaceuticals	Robert W. Baird	Reiterated Rating
4/17/2020	Reata Pharmaceuticals	Jefferies Financial Group	Boost Price Target
11/13/2019	Reata Pharmaceuticals	National Securities	Downgrade
10/28/2020	PTC Therapeutics	UBS Group	Initiated Coverage
7/20/2020	PTC Therapeutics	Cowen	Reiterated Rating
7/20/2020	PTC Therapeutics	SunTrust Banks	Boost Price Target

(Data available from 4/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources